Colorectal Cancer Clinical Trials in Omaha, Nebraska

5 studies are recruiting for colorectal cancer in Omaha, Nebraska right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Lead-212 PSV359 Therapy for Patients With Solid Tumors

   Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

   Stage

   Phase 1

   Ages

   18 to 90

   Site

   Nebraska Cancer Specialists, Omaha, Nebraska

   Locations

   16 in total

   Run by

   Perspective Therapeutics

   See if you can join NCT06710756 on ClinicalTrials.gov

2. 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

   This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with relapsed/refractory, locally advanced inoperable, or metastatic solid tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Nebraska Cancer Specialists, Omaha, Nebraska

   Locations

   5 in total

   Run by

   Radiopharm Theranostics, Ltd

   See if you can join NCT07189871 on ClinicalTrials.gov

3. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

   The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Nebraska Cancer Specialists, Omaha, Nebraska

   Locations

   32 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06445062 on ClinicalTrials.gov

4. Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

   The primary objective of this study is to evaluate the effectiveness of zanzalintinib + Pembrolizumab (+) berahyaluronidase alfa and zanzalintinib alone compared with placebo.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Oncology Hematology West, PC dba Nebraska Cancer Specialists - Methodist, Omaha, Nebraska

   Locations

   13 in total

   Run by

   Exelixis

   See if you can join NCT07750158 on ClinicalTrials.gov

5. Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

   The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Nebraska Cancer Specialists, Omaha, Nebraska

   Locations

   20 in total

   Run by

   Tempus AI

   See if you can join NCT05234177 on ClinicalTrials.gov